ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
In vivo and in silico approaches for evaluating nerolidol-β-cyclodextrin nanoparticles: Antioxidant potential and hormonal modulation in DMBA-induced mammary carcinoma.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to investigate the chemopreventive effects of nerolidol-β-cyclodextrin nanoparticles (NER-βCD-NPs) on DMBA-induced oxidative stress, lipid, and hormonal disturbances in rats and to characterize their physicochemical properties and molecular interactions with breast cancer targets. NER-βCD-NPs were prepared and HR-TEM and SAED were used for NPs characterization. A total of 36 rats were divided into six groups. Group I served as the control. Group II received a single dose of DMBA (25 mg/rat). Groups III-V were DMBA-injected and treated with NER-βCD-NPs (5, 10, and 20 mg/kg). Group VI received only NER-βCD-NPs (20 mg/kg). After 16 weeks, rats were sacrificed for biochemical and hormonal analysis. Molecular docking of nerolidol was performed with breast cancer targets (ER, PR, and HER2). HR-TEM analysis showed well-defined, near-spherical NER-βCD-NPs with an average size of 27.6 nm. SAED patterns confirmed their polycrystalline structure. DMBA-alone rats exhibited significant decreases in antioxidant activity and increases in lipid peroxidation, lipid profile markers (TC, TG, FFA, and PL), and hormonal levels (ER, PR, and HER2). Treatment with NER-βCD-NPs dose dependently restored antioxidant status, reduced lipid peroxidation and lipid profile disturbances, and normalized hormonal markers. Molecular docking revealed nerolidol exhibited favorable binding to ER (- 7.2 kcal/mol), PR (- 6.6 kcal/mol), and HER2 (- 7.6 kcal/mol), comparable to standard hormonal drugs, with hydrophobic interactions and hydrogen bonds. NER-βCD-NPs significantly ameliorate DMBA-induced oxidative stress, lipid dysregulation, and hormonal imbalance in rats, supported by strong molecular interactions with key breast cancer targets. These findings suggest the potential of NER-βCD-NPs as a promising, safe, and effective chemopreventive agent.
Indexed as
Identifiers
41351794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.